FDA Approves Two Medications to Treat HIV Infection: Cobicistat (Brand Name: Tybost) and Elvitegravir (Brand Name: Vitekta)
"On September 24, 2014, FDA approved Tybost (cobicistat) 150 mg tablets. Tybost is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection."
For more information on cobicistat, view the FDA press release.
"On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets. Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults."
For more information on elvitegravir, view the FDA press release.
The labeling for both drugs will be available soon at the FDA website.
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Department of Health | Health | HIV AIDS | Infectious Diseases | Norvir | Prezista | Websites